Raptor Pharmaceutical Corp 4
4 · Raptor Pharmaceutical Corp · Filed Oct 26, 2016
Insider Transaction Report
Form 4
Smith Michael P
Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2016-10-25−84,751→ 0 totalExercise: $3.74Exp: 2026-02-09→ Common Stock (84,751 underlying) - Disposition to Issuer
Common Stock
2016-10-25$9.00/sh−22,607$203,463→ 0 total
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger dated as of September 12, 2016, by and among Raptor Pharmaceutical Corp., Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent (the "Merger Agreement"), on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes.
- [F2]Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.